Current Atherosclerosis Reports

OCT 15, 2026 · JOURNAL ARTICLE

In-vivo CRISPR/Base-Editing “One-Shot” Therapies Targeting PCSK9

Current Atherosclerosis Reports

PURPOSE OF REVIEW: To assess and present the current state of gene editing for reduction of atherosclerotic cardiovascular disease (ASCVD) with emphasis on technology and ongoing t

OCT 14, 2026 · JOURNAL ARTICLE

RNA-Based Therapies for Lipoprotein(a) Reduction: Antisense Oligonucleotides, Small Interfering RNAs, and Emerging Platforms

Current Atherosclerosis Reports

Abstract Purpose of Review Lipoprotein(a) [Lp(a)] is an independent, genetically determined, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific

AUG 13, 2026 · JOURNAL ARTICLE

Novel Lipoprotein (a) Therapies: A Comprehensive Review

Current Atherosclerosis Reports

A comprehensive narrative review synthesizing phase 1–3 trial data, regulatory updates, and pipeline information to inform clinical and research practice regarding emerging Lp(a) therapies.